1 active not recruiting, 1 terminated, 1 withdrawn. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Terminated 1 |
Follow IDH2 Gene Mutation: new trials by email Literature Review of IDH2 Gene Mutation trials Research Report on IDH2 Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms Ivosidenib, Enasidenib, Fedratinib - IDH Mutation, IDH1 Mutation | Phase 1 | Withdrawn | University of Chicago | 2021-10-29 | 2024-07-31 | |
| Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Enasidenib, Venetoclax - Acute Myeloid Leukemia, Relapsed Cancer | Phase 1 / Phase 2 | Terminated | University Health Network, Toronto | 27 | 2020-11-05 | 2024-01-24 |
| BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas PARP Inhibitor BGB-290, Temozolomide (TMZ) - Glioblastoma, IDH1 Gene Mutation | Phase 1 | Active not recruiting | University of California, San Francisco | 78 | 2019-04-03 | 2026-03-13 |
Glioblastoma (1) · Glioma (1) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Recurrence (1)
Neoplasms by Histologic Type (3) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Neoplasms (2) · Astrocytoma (1) · Bone Marrow Diseases (1) · Disease Attributes (1) · Leukemia (1) · Leukemia, Myeloid (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Nerve Tissue (1) · Neoplasms, Neuroepithelial (1) · Neuroectodermal Tumors (1)
enasidenib (2) · Temozolomide (1) · fedratinib (1) · ivosidenib (1) · pamiparib (1) · venetoclax (1)
University Health Network, Toronto (1) · University of California, San Francisco (1) · University of Chicago (1)
United States (2) · Canada (1)
Olatoyosi Odenike, MD (1) · Sabine Mueller, MD, PhD (1) · Steven Chan, M.D. (1)